ESR1 and neoplasm: However, in the EORTC 10994/BIG 1–00 trial, the presence of p53 mutations was found to be predictive of poor outcomes in patients treated with either anthracycline or taxane-based regimen [51], which may be caused by poor tumor differentiation and low ER expression in p53-positive patients.